Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, Torp-Pedersen C, Ge H, Moran SA, Shepherd GM, James WP; SCOUT Investigators. Van Gaal LF, et al. Among authors: coutinho w. Diabetes Obes Metab. 2010 Jan;12(1):26-34. doi: 10.1111/j.1463-1326.2009.01090.x. Epub 2009 Sep 16. Diabetes Obes Metab. 2010. PMID: 19758358 Clinical Trial.
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP; SCOUT Investigators. Sharma AM, et al. Among authors: coutinho w. Diabetes Obes Metab. 2009 Mar;11(3):239-50. doi: 10.1111/j.1463-1326.2008.00930.x. Epub 2008 Jul 29. Diabetes Obes Metab. 2009. PMID: 18671798 Clinical Trial.
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP; SCOUT Investigators. Caterson ID, et al. Among authors: coutinho w. Diabetes Obes Metab. 2012 Jun;14(6):523-30. doi: 10.1111/j.1463-1326.2011.01554.x. Epub 2012 Jan 18. Diabetes Obes Metab. 2012. PMID: 22192338 Clinical Trial.
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Seimon RV, Espinoza D, Finer N, James WP, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Seimon RV, et al. Among authors: coutinho w. Int J Obes (Lond). 2015 May;39(5):849-57. doi: 10.1038/ijo.2014.211. Epub 2014 Dec 18. Int J Obes (Lond). 2015. PMID: 25520249 Clinical Trial.
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P; SCOUT Investigators. Maggioni AP, et al. Among authors: coutinho w. J Cardiovasc Pharmacol. 2008 Nov;52(5):393-402. doi: 10.1097/FJC.0b013e31818713d6. J Cardiovasc Pharmacol. 2008. PMID: 19033818 Clinical Trial.
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C; SCOUT Executive Steering Committee; SCOUT investigators. Andersson C, et al. Among authors: coutinho w. Metabolism. 2009 Aug;58(8):1109-15. doi: 10.1016/j.metabol.2009.04.003. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19454355 Clinical Trial.
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period.
Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, Sharma AM, Ge H, Santoro D, Shepherd G, James P; SCOUT Investigators. Caterson I, et al. Among authors: coutinho w. Obesity (Silver Spring). 2010 May;18(5):987-94. doi: 10.1038/oby.2009.327. Epub 2009 Oct 8. Obesity (Silver Spring). 2010. PMID: 19816415 Free article. Clinical Trial.
Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial.
Maggioni AP, Caterson ID, Urso R, Coutinho W, Finer N, Van Gaal L, Legler UF, Sharma AM, Seimon RV, Sweeting A, Torp-Pedersen C, James WP. Maggioni AP, et al. Among authors: coutinho w. J Cardiovasc Med (Hagerstown). 2017 Mar;18(3):144-151. doi: 10.2459/JCM.0000000000000492. J Cardiovasc Med (Hagerstown). 2017. PMID: 28002198 Clinical Trial.
100 results